HomeNewsThe second domestically produced ECMO product of Aerospace Science and Technology for...

The second domestically produced ECMO product of Aerospace Science and Technology for high-end medical treatment was approved for listing-Chinanews.com



The second domestically produced ECMO product of Aerospace Science and Technology for high-end medical treatment was approved for listing



Chinanews.com, Beijing, January 17 (Ma Shuisha) On January 17, 2023, after review, the State Food and Drug Administration adopted a conditional approval method and urgently approved Aerospace New Long March Medical Devices (Beijing) Co., Ltd. (Long March for short) Huisheng-I ECMO, an extracorporeal lung support auxiliary device developed by China Medical, was registered and launched. This product is the second approved domestic ECMO product.

It is reported that the technology of this product is independently controllable and has completely independent intellectual property rights. It is transformed from the aerospace technology adopted by the rocket flight control execution system-servo mechanism. It is an important achievement of China’s aerospace technology in the high-end medical field. Performance and indicators Reach the international level of similar products.

ECMO is mainly used to provide continuous extracorporeal breathing and blood circulation support for patients with severe cardiopulmonary failure. The core components generally include artificial heart (centrifugal pump host and centrifugal pump head) and artificial lung (membrane lung), which can replace human heart for a long time. The heart and lung function of the patient can maintain the patient’s blood pressure and blood oxygen, and win precious time for the rescue of critically ill patients. Therefore, it is regarded as the “gatekeeper” in the ICU to save lives.

Long March Medical has cooperated with Peking Union Medical College Hospital, China-Japan Friendship Hospital, Chinese People’s Liberation Army General Hospital, Tianjin Taixin Hospital, Tianjin Medical University Second Hospital and other domestic top hospitals to carry out preclinical large animal experiments and clinical trials for elderly critically ill patients. The treatment effect is good, fully verifying the reliability, safety and effectiveness of the product.

It is understood that Long March Medical is a wholly-owned subsidiary of Beijing Precision Mechatronics Control Equipment Research Institute, which is affiliated to the First Academy of China Aerospace Science and Technology Corporation. control. (Finish)


Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!

Popular Articles